Background: Cardiovascular disease is common in patients with chronic kidney disease (CKD) and often results in severely calcified lesions that are difficult to cross and treat. As a result, this population may have worse clinical outcomes following percutaneous coronary intervention compared to patients without CKD. Clinical trials typically exclude this patient population. Methods: ORBIT II patients with severely calcified coronary lesions treated with the coronary Orbital Atherectomy System (OAS) were divided into three groups based on the estimated glomerular filtration rate (eGFR, mL/min/1.73m 2 ) at baseline: I (CKD Stages 3-5), eGFR<60 (n¼115); II (CKD stages 1-2), eGFR 60 to <90 (n¼218); and III (normal), eGFR!90 (n¼108). Results: Patients in groups I and II were older (p<0.0001), and there were more females in these two groups than in group III (p¼0.0468). History of previous stroke (p¼0.0351) was more prevalent in groups I and II. In addition, the total length of calcium was significantly longer in group II (p¼0.0003). Similar successful stent delivery occurred in 97.4%, 97.2% and 99.1% (p¼0.7006) of cases with <50% residual stenosis in 99.1%, 98.2% and 99.1% (p¼0.8779) of subjects in groups I, II and III, respectively. Statistically similar low rates of severe dissection (1.7%, 5.5%, 0.9%: p¼0.0709), perforation (2.6%, 1.8%, 0.9%: p¼0.7343), persistent slow flow (0.9%, 1.4%, 0.0%: p¼0.8110), and abrupt closure (1.7%, 1.8%, 1.9%: p¼1.0000) were observed in groups I, II, and III, respectively. The 30 day Freedom from MACE rates in groups I (87.8%), II (87.1%), and III (96.3%) were similar (p¼0.0555). Conclusion: Severely calcified coronary lesion pre-treatment with the coronary OAS resulted in similar 30 day Freedom from MACE rates and low rates of procedural complications in CKD patients compared with the non-CKD patients despite the older demographic and longer length of calcium in the CKD patients. Background: Previous studies have shown a negative correlation between female gender and adverse events after percutaneous coronary intervention (PCI). In this analysis, we evaluate the procedural and 30-day outcomes of male and female patients in the ORBIT II Trial. Methods: The ORBIT II Trial, a prospective, multicenter, non-blinded clinical trial that enrolled 443 consecutive patients, was designed to evaluate the safety and efficacy of the coronary Orbital Atherectomy System to prepare de novo, severely calcified coronary lesions for stent placement. Procedural and 30-day outcomes in male patients (N¼286) were compared to female patients (N¼157). The primary safety endpoint was freedom from major adverse cardiac events (MACE) at 30 days post-procedure. The primary efficacy endpoint was procedural success defined as stent delivery with a residual stenosis of <50% without the occurrence of an inhospital MACE. Results: Compared to males, females were older (p¼0.0011) and had lower eGFR at baseline (p¼0.0024). However males had a higher rate of previous coronary artery bypass graft (p¼0.0048 
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revascularization (TVR/TLR) (1.8% vs. 0.6%, p¼0.3584) and cardiac death (0% vs. 0.7%, p¼0.9976). Conclusion: This sub-analysis of the ORBIT II study demonstrates that males and females treated with orbital atherectomy for severely calcified coronary arteries (generally regarded as high-risk revascularization) demonstrate similar 30-day outcomes. In the context of the larger study, one can presume that the novel coronary Orbital Atherectomy System is a safe and effective adjunctive therapy for severely calcified coronary lesions in both men and women. Background: The use of the Transradial access (TR) for the treatment of Coronary Bifurcation Lesions (CBL) with Percutaneous Coronary Intervention (PCI) can be limited where a two stent strategy is required as larger sheath and guide catheters are required to facilitate stent delivery. With the development of newer dedicated bifurcation stents, there is an increasing trend of these stents to be adopted in PCI centres to treat CBL's. We report our experience of the use of the TrytonÔ dedicated side branch bifurcation stent at our default TR centre where 90% of all PCI are carried out via the TR. Methods: This was a prospective study of all patients who were found suitable to undergo PCI to CBL's using the Tryton stent between September 2009 and June 2013. Data on patient demographics and procedure characteristics was collected from the local hospital database. Results: 36 patients (Male 69.4%, age 68.1 years) underwent PCI using the 19mm long TrytonÔ bifurcation stent. Most of the CBL's treated were located in the LAD/Branch (52.8%), followed by the Circumflex/Branch (27.8%), Left main stem/Branch (13.9%), RCA/Branch (2.7%) and LIMA graft (2.7%). TrytonÔ stents dimensions (Side branch/Main branch diameters) deployed were (2.5/2.5mm -11.1%; 2.5/3.0mm -25%; 2.5/3.5mm -47.2%; 3.0/3.5mm -8.3% and 3.5/4.0mm -8.3%). 91.6% of cases were carried out via 6F guide catheters with the remaining cases carried out via the 7F. Mean contrast volume, radiation dose and fluoroscopy times were 306 mls, 98.8 Gy/cm2 and 28.2 minutes respectively. 94.4% of all cases were successfully carried out via the TR route with remaining cases switching to the transfemoral route to successfully complete the procedure. Conclusions: When treating CBL's, a wide range of TrytonÔ dedicated side branch stents can be safely and effectively deployed via the TR route using 6F/7F Guide catheter systems. This can avoid the use of the transfemoral route and its associated potential vascular complications. Background: Coronary artery bypass graft (CABG) surgery is commonly performed to treat ischemic heart disease, but long term benefits are limited by patency of saphenous vein grafts. Both statin medications and aspirin hold class I indications for all post-CABG patients and should be continued indefinitely unless contraindication exists. Unfortunately, there is limited data regarding long-term usage of these medications. We assessed utilization rates among post-CABG patients without documented contraindication. Methods: A retrospective analysis of post-CABG patients presenting to the Thomas Jefferson University cardiac catheterization laboratory for a catheterization procedure at least 3 years after surgery was performed. Inpatient and outpatient records were reviewed to assess prescribing patterns of these medications, as well as other pertinent clinical and laboratory data. Results: The study population consisted of 381 consecutive patients who presented on average 11 AE 6 years from the time of CABG. Mean age of our study population was 69 AE 11 years with 78% male. The most common indications for catheterization were unstable angina (36%), non-STEMI (22%), and an abnormal stress test (15%). Only 67% of patients were being prescribed a statin, while 75% were prescribed aspirin. Only 52% were prescribed both at the time of catheterization. Three percent had a documented intolerance to statin therapy. Patients prescribed a statin had a significantly lower mean LDL (87 vs. 106 [p<0.01] 
